stockrowIGC Pharma, Inc.
IGC Pharma, Inc.’s revenue for fiscal 2025 (year ended March 2025) was $1.3 million, down 5.50% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- 0.00%
- Free cash flow
- −45.3%
- Total debt
- +558.3%
Quarter to September 2026, against a year earlier
Follow IGC
Alert me
IGC Pharma, Inc. (IGC) EV/Sales
As of 6 November 2026, IGC Pharma, Inc. (IGC) trades at a EV/Sales of 19.3×. Over the past ten years it has ranged from −3.4× (December 2018) to 309× (July 2021); the current reading is higher than 54% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 18.1× | (11.04%) |
| FY2024 | 20.3× | 24.98% |
| FY2023 | 16.2× | (82.65%) |
| FY2022 | 93.7× | 37.72% |
| FY2021 | 68.0× | 3,569.44% |
| FY2020 | 1.9× | (79.39%) |
| FY2019 | 9.0× | 42.18% |
| FY2018 | 6.3× | (70.48%) |
| FY2017 | 21.4× | 1,594.42% |
| FY2016 | 1.3× | 6.15% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 27.3× | 7.91% |
| Jun 2026 | 25.3× | 12.42% |
| Mar 2026 | 22.5× | (33.05%) |
| Sep 2025 | 33.6× | 74.35% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ATOS Atossa Therapeutics, Inc. compare | −174× |
| FLNA Cassava Sciences, Inc. compare | n/m |
| NXTC NextCure, Inc. compare | 0.4× |
| CRVO CervoMed Inc. compare | 0.6× |
| EVAX Evaxion A/S - Sponsored ADR compare | 1.4× |
| CELU Celularity, Inc. compare | 3.4× |
| IGC IGC Pharma, Inc. | 19.3× |
| CVM Cel-Sci Corporation compare | 27.6× |
| MCRB Seres Therapeutics, Inc. compare | 49.2× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)